Cargando…

Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection

Booster immunizations and breakthrough infections can elicit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant neutralizing activity. However, the durability of the neutralization response is unknown. We characterize the sensitivity of BA.1, BA.2, BA.2.75, BA.4/BA.5, BF...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Ka-Li, Jiang, Xiao-Lin, Zhan, Bing-Dong, Wang, Xue-Jun, Xia, Xian, Cao, Guo-Ping, Sun, Wen-Kui, Huang, Peng-Xiang, Zhang, Jin-Zhong, Gao, Yu-Ling, Dai, Er-Hei, Gao, Hui-Xia, Ma, Mai-Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906998/
https://www.ncbi.nlm.nih.gov/pubmed/36774551
http://dx.doi.org/10.1016/j.celrep.2023.112075
_version_ 1784884083308888064
author Zhu, Ka-Li
Jiang, Xiao-Lin
Zhan, Bing-Dong
Wang, Xue-Jun
Xia, Xian
Cao, Guo-Ping
Sun, Wen-Kui
Huang, Peng-Xiang
Zhang, Jin-Zhong
Gao, Yu-Ling
Dai, Er-Hei
Gao, Hui-Xia
Ma, Mai-Juan
author_facet Zhu, Ka-Li
Jiang, Xiao-Lin
Zhan, Bing-Dong
Wang, Xue-Jun
Xia, Xian
Cao, Guo-Ping
Sun, Wen-Kui
Huang, Peng-Xiang
Zhang, Jin-Zhong
Gao, Yu-Ling
Dai, Er-Hei
Gao, Hui-Xia
Ma, Mai-Juan
author_sort Zhu, Ka-Li
collection PubMed
description Booster immunizations and breakthrough infections can elicit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant neutralizing activity. However, the durability of the neutralization response is unknown. We characterize the sensitivity of BA.1, BA.2, BA.2.75, BA.4/BA.5, BF.7, BQ.1.1, and XBB against neutralizing antibodies from vaccination, hybrid immunity, and breakthrough infections 4–6 months after vaccination and infection. We show that a two-dose CoronaVac or a third-dose ZF2001 booster elicits limited neutralization against Omicron subvariants 6 months after vaccination. Hybrid immunity as well as Delta, BA.1, and BA.2 breakthrough infections induce long-term persistence of the antibody response, and over 70% of sera neutralize BA.1, BA.2, BA.4/BA.5, and BF.7. However, BQ.1.1 and XBB, followed by BA.2.75, are more resistant to neutralization, with neutralizing titer reductions of ∼9- to 41-fold, ∼16- to 63-fold, and ∼4- to 25-fold, respectively. These data highlight additional vaccination in CoronaVac- or ZF2001-vaccinated individuals and provide insight into the durability of neutralization against Omicron subvariants.
format Online
Article
Text
id pubmed-9906998
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Author(s).
record_format MEDLINE/PubMed
spelling pubmed-99069982023-02-08 Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection Zhu, Ka-Li Jiang, Xiao-Lin Zhan, Bing-Dong Wang, Xue-Jun Xia, Xian Cao, Guo-Ping Sun, Wen-Kui Huang, Peng-Xiang Zhang, Jin-Zhong Gao, Yu-Ling Dai, Er-Hei Gao, Hui-Xia Ma, Mai-Juan Cell Rep Report Booster immunizations and breakthrough infections can elicit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant neutralizing activity. However, the durability of the neutralization response is unknown. We characterize the sensitivity of BA.1, BA.2, BA.2.75, BA.4/BA.5, BF.7, BQ.1.1, and XBB against neutralizing antibodies from vaccination, hybrid immunity, and breakthrough infections 4–6 months after vaccination and infection. We show that a two-dose CoronaVac or a third-dose ZF2001 booster elicits limited neutralization against Omicron subvariants 6 months after vaccination. Hybrid immunity as well as Delta, BA.1, and BA.2 breakthrough infections induce long-term persistence of the antibody response, and over 70% of sera neutralize BA.1, BA.2, BA.4/BA.5, and BF.7. However, BQ.1.1 and XBB, followed by BA.2.75, are more resistant to neutralization, with neutralizing titer reductions of ∼9- to 41-fold, ∼16- to 63-fold, and ∼4- to 25-fold, respectively. These data highlight additional vaccination in CoronaVac- or ZF2001-vaccinated individuals and provide insight into the durability of neutralization against Omicron subvariants. The Author(s). 2023-02-28 2023-01-27 /pmc/articles/PMC9906998/ /pubmed/36774551 http://dx.doi.org/10.1016/j.celrep.2023.112075 Text en © 2023 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Report
Zhu, Ka-Li
Jiang, Xiao-Lin
Zhan, Bing-Dong
Wang, Xue-Jun
Xia, Xian
Cao, Guo-Ping
Sun, Wen-Kui
Huang, Peng-Xiang
Zhang, Jin-Zhong
Gao, Yu-Ling
Dai, Er-Hei
Gao, Hui-Xia
Ma, Mai-Juan
Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
title Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
title_full Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
title_fullStr Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
title_full_unstemmed Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
title_short Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
title_sort durability of neutralization against omicron subvariants after vaccination and breakthrough infection
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906998/
https://www.ncbi.nlm.nih.gov/pubmed/36774551
http://dx.doi.org/10.1016/j.celrep.2023.112075
work_keys_str_mv AT zhukali durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection
AT jiangxiaolin durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection
AT zhanbingdong durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection
AT wangxuejun durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection
AT xiaxian durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection
AT caoguoping durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection
AT sunwenkui durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection
AT huangpengxiang durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection
AT zhangjinzhong durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection
AT gaoyuling durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection
AT daierhei durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection
AT gaohuixia durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection
AT mamaijuan durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection